NCT05347069 Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
| NCT ID | NCT05347069 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Takeshi Morimoto |
| Condition | Stable Angina Pectoris |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,890 participants |
| Start Date | 2022-06-14 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 2,890 participants in total. It began in 2022-06-14 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.
Eligibility Criteria
Inclusion Criteria: * Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization * Patients for whom consent can be obtained Exclusion Criteria: * Patients with history of acute coronary syndromes (ACS) * Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) * Patients with left main trunk stenosis (≥50%) * Patients for whom aspirin administration is mandatory * Patients undergoing antithrombotic therapy other than aspirin * Patients with atrial fibrillation * Patients with history of stroke within six months * Patients scheduled for major surgical procedures that will require aspirin discontinuation * Patients with contraindication of aspirin * Patients expected to have a prognosis of 1 year or less due to comorbidities * Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization * Patients who are judged by attending physicians to be inappropriate to participate in this study
Contact & Investigator
Takeshi Kimura, MD, PhD
PRINCIPAL INVESTIGATOR
Kyoto University, Graduate School of Medicine
Frequently Asked Questions
Who can join the NCT05347069 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Stable Angina Pectoris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05347069 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05347069 currently recruiting?
Yes, NCT05347069 is actively recruiting participants. Contact the research team at taketaka@kuhp.kyoto-u.ac.jp for enrollment information.
Where is the NCT05347069 trial being conducted?
This trial is being conducted at Kyoto, Japan.
Who is sponsoring the NCT05347069 clinical trial?
NCT05347069 is sponsored by Takeshi Morimoto. The principal investigator is Takeshi Kimura, MD, PhD at Kyoto University, Graduate School of Medicine. The trial plans to enroll 2,890 participants.